You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Abbott said that greater than 90 percent of the issued and outstanding shares of preferred stock had been tendered as of Sept. 15.
The CDC received clearance for a number of influenza panels and kits. Agilent's assay for postnatal CNV detection, and Abbott's hematocrit test were also cleared.
The firm extended its cash tender offer for all outstanding shares of Alere's Series B convertible perpetual preferred stock until the end of the day on Sept. 15.
As part of the contract, Abbott will supply analytical equipment and consumables, including the Alinity ci and Alinity h series diagnostics instruments.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
Alere's financial results in the prior-year period reflected restatements of revenues stemming from incorrectly recorded revenue transactions.
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
The test, which is based on the company's beta-galactosidase enzyme technology, is cleared for the qualitative detection of fentanyl in urine.
Alere is divesting Epocal as it seeks regulatory approval of its merger with Abbott. Based in Ottawa, Ontario, Epocal develops point-of-care blood diagnostic systems.